GPC3 and hepatocellular carcinoma: Building on this molecular design, BTOGP‐GPC3 nanoparticles (NPs) are further developed by conjugating the hepatocellular carcinoma (HCC)‐specific targeting molecule Glypican‐3 peptide (GPC3).